Star Combo Pharma Limited

ASX:S66 Stock Report

Market Cap: AU$16.2m

Star Combo Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Star Combo Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth13.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Some Star Combo Pharma Limited (ASX:S66) Shareholders Look For Exit As Shares Take 31% Pounding

Nov 11
Some Star Combo Pharma Limited (ASX:S66) Shareholders Look For Exit As Shares Take 31% Pounding

Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up

Aug 23
Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up

Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger

Aug 13
Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger

Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 12
Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price

May 12
Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price

Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon

Mar 20
Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon

Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?

Nov 21
Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?

Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Mar 02
Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt

Dec 24
Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Star Combo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:S66 - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024261-20N/A
3/31/2024261-11N/A
12/31/202325012N/A
9/30/202325-202N/A
6/30/202325-4-12N/A
3/31/202324-5-31N/A
12/31/202223-5-5-1N/A
9/30/202223-3-60N/A
6/30/202223-1-71N/A
3/31/202224-5-71N/A
12/31/202124-8-62N/A
9/30/202126-8-71N/A
6/30/202127-8-70N/A
3/31/202130-3-60N/A
12/31/2020331-6-1N/A
9/30/2020361-5-1N/A
6/30/2020390-4-1N/A
3/31/202038-1-50N/A
12/31/201937-2-60N/A
9/30/201929-2-6-1N/A
6/30/201922-2-6-2N/A
3/31/201917-2-6-3N/A
12/31/201812-3-5-4N/A
9/30/201812-2-4-3N/A
6/30/201811-2-3-2N/A
6/30/2017102N/A1N/A
6/30/201692N/AN/AN/A
6/30/201570N/AN/AN/A
6/30/201450N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if S66's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if S66's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if S66's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if S66's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if S66's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if S66's Return on Equity is forecast to be high in 3 years time


Discover growth companies